Lipoxal (oxaliplatin) / Regulon - LARVOL DELTA

A 58-Year-Old Man with Locally Advanced Pancreatic Adenocarcinoma: Episode 8 Treatment Decision and Conclusion (Targeted Oncology) - "Panelist discusses how NALIRIFOX (liposomal irinotecan, 5-fluorouracil, leucovorin, oxaliplatin) represents a reasonable treatment option for patients with excellent performance status and locally advanced pancreatic adenocarcinoma, requiring close monitoring and proactive toxicity management to maximize outcomes."

Video

Targeting the KLF5/PI3K/AKT axis as a therapeutic strategy to overcome neoadjuvant chemoresistance in colorectal cancer. (PubMed, Front Immunol) - "Through high-throughput screening, GDC-0941, a PI3K/AKT inhibitor, emerged as a promising therapeutic agent that synergistically enhanced oxaliplatin efficacy and overcame resistance in preclinical models. Targeting the KLF5/PI3K/AKT axis may enhance chemotherapy efficacy and overcome drug resistance in CRC."

Journal • Colorectal Cancer • Oncology • Solid Tumor • KLF5

Cancer Vaccines Approach New Horizons in Melanoma and Other Solid Tumors (OncLive) - "Patrick Ott, MD, PhD, discusses the investigation of cancer vaccines, highlighting the clinical implications of this treatment modality in melanoma."

Audio

IDEA Collaboration Affects Choice of Chemotherapy Regimen, Treatment Duration in Stage III Colon Cancer (OncLive) - "'Even though [the IDEA collaboration] suggested that certain patients may have noninferior outcomes from a shortened duration of chemotherapy, because the overall results of the study didn’t apply to all patients, we were curious to see how prescribing patterns would change,' Daniel H. Ahn, DO...said in an interview with OncLive."

Interview

Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer | Journal of Clinical Oncology

Use Of Acupuncture And Acupressure In Addition To Standard-Of-Care Cryotherapy To Decrease Chemotherapy-Associated Neuropathy Symptoms In Patients With Gastrointestinal Malignancies Receiving Oxaliplatin-Based Chemotherapy Regimens: Study Protocol For A Randomized, Controlled Pilot And Feasibility Study (SIO-Canada 2023) - P=NA | N=56 | "Effective interventions are needed to prevent and treat CIPN in GI oncology patients, as CIPN can be dose-limiting and decrease adherence to life-saving treatment. Acupuncture and acupressure may improve CIPN incidence and severity. Acupuncture research protocols incorporated into standard-of-care workflow are needed. Results anticipated in 2024."

Clinical data

Use Of Acupuncture And Acupressure In Addition To Standard-Of-Care Cryotherapy To Decrease Chemotherapy-Associated Neuropathy Symptoms In Patients With Gastrointestinal Malignancies Receiving Oxaliplatin-Based Chemotherapy Regimens: Study Protocol For A Randomized, Controlled Pilot And Feasibility Study (SIO-Canada 2023) - P=NA | N=56 | "Effective interventions are needed to prevent and treat CIPN in GI oncology patients, as CIPN can be dose-limiting and decrease adherence to life-saving treatment. Acupuncture and acupressure may improve CIPN incidence and severity. Acupuncture research protocols incorporated into standard-of-care workflow are needed. Results anticipated in 2024."

Clinical data

Use Of Acupuncture And Acupressure In Addition To Standard-Of-Care Cryotherapy To Decrease Chemotherapy-Associated Neuropathy Symptoms In Patients With Gastrointestinal Malignancies Receiving Oxaliplatin-Based Chemotherapy Regimens: Study Protocol For A Randomized, Controlled Pilot And Feasibility Study (SIO-Canada 2023) - P=NA | N=56 | "Effective interventions are needed to prevent and treat CIPN in GI oncology patients, as CIPN can be dose-limiting and decrease adherence to life-saving treatment. Acupuncture and acupressure may improve CIPN incidence and severity. Acupuncture research protocols incorporated into standard-of-care workflow are needed. Results anticipated in 2024."

Clinical data

Induction Chemotherapy with FTD/TPI and Oxaliplatin in Resectable EGAC: Preliminary Phase II Study Results (Oncology Tube) - "Sarbajit Mukherjee, MD...conducted a study to investigate the efficacy of a novel treatment approach for localized esophagogastric adenocarcinoma (EGAC). The standard treatment of pre-operative chemoradiation (CRT) followed by surgery leads to a pathologic complete response (pCR) rate of 20%. However, achieving pCR is associated with improved overall survival (OS). In this study, physicians aimed to increase the pCR rate by administering an innovative combination of FTD/TPI and oxaliplatin as induction chemotherapy (IC) prior to standard CRT."

Video

ASCO 2023: Will Gastrointestinal Cancer Studies Affect Practice? (Cancer Therapy Advisor) - "'It's really very exciting because in an era when we think about novel therapies being the newsmakers, I think this idea of, 'Can we find ways to make treatments better tolerated and improve patient quality of life?' is really equally important,' Dr Kunz said."

Media quote

Design and Goals of the Phase 3 MOUNTAINEER-03 Study in mCRC (Targeted Oncology) - "Tanios S. Bekaii-Saab, MD, FACP, discusses the patient population, methods, and design utilized in the phase 3 MOUNTAINEER-03 study."

Video

Recent advances in the management of pancreatic cancer (YouTube) - "Andrew Ko, MD, FASCO, University of California, San Francisco, CA, discusses developments in the treatment of pancreatic cancer, including findings from the Phase III NAPOLI-3 trial (NCT04083235), which compared liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX) to nab-paclitaxel with gemcitabine in previously untreated patients with metastatic pancreatic ductal adenocarcinoma. Dr Ko also talks on the future role of targeted therapies such as sotorasib and adagrasib in KRAS G12C-mutant pancreatic cancer, and immunotherapy."

Interview • Video

NALIRIFOX Improves OS in Pancreatic Cancer (Targeted Oncology) - "'I would argue that [the data from] this randomized trial of NAPOLI 3 should supersede our opinion about the efficacy of these regimens mFOLFIRINOX and nabpaclitaxel/gemcitabine] in the metastatic setting,' Goff said."

Insights on Pancreatic Cancer Microbiome, Phase 2 Esophageal Cancer Study Top Roswell Park’s AACR Presentations (Roswell Park Comprehensive Cancer Center) - "Sarbajit Mukherjee, MD...will present preliminary results on a phase 2 study looking at Trifluridine/tipiracil (FTD/TPI) and oxaliplatin as induction chemotherapy (IC) in resectable esophageal and gastroesophageal junction adenocarcinoma (EGAC) (Abstract CT146/8)."

FTD/TPI plus oxaliplatin well-tolerated but not broadly effective as treatment for esophageal cancer (Medical Xpress) - "'We report here that the novel combination of trifluridine/tipiracil and oxaliplatin is well-tolerated and has activity in esophageal cancer, but that this combination does not improve outcomes in all patients with esophageal cancer,' Dr. Mukherjee says, noting that the team is performing a correlative analysis seeking to identify whether a subgroup of patients may benefit from induction chemotherapy with this regimen."

Media quote

ASCO Gastrointestinal Cancers Symposium 2023 : Episode 6: Opportunities for Innovation in GI Cancer Treatment Landscape (AJMC) - "John L. Marshall, MD: We have to go back and remember that GI [gastrointestinal] cancers are the most common, most fatal group of cancers on our planet. With pancreas cancer, we still have almost not moved the bar at all. Gastroesophageal, gastric cancers are miserable diseases to have and to take care of, frankly. We have made some progress in colon, we're making progress in liver and bile duct [cancers]."

Video

Dr Malalur on the Implications of NALIRIFOX in Pancreatic Ductal Adenocarcinoma (OncLive) - "The efficacy and safety data point to NALIRIFOX as a potential new first-line treatment option for patients with metastatic PDAC, and the varying TEAEs associated with the regimen and nab-paclitaxel/gemcitabine could allow for different choices for patients in this setting, Malalur concludes."

Video

Poorer Survival in Stage III Colon Cancer With Greater Inflammation After Surgery and Prior to Adjuvant Therapy (THE ASCO POST) - P=NA | N=1,494 | "In a study reported in JAMA Oncology...Jeffrey ­Meyerhardt, MD, MPH...and colleagues found that higher levels of inflammatory biomarkers measured after surgery but before starting chemotherapy were associated with poorer survival in patients with stage III colon cancer from the CALGB/SWOG 80702 adjuvant chemotherapy trial."

Clinical data

Phase III Trials Confirm Benefit of First-Line Anti–PD-1 Plus Chemotherapy in Gastric Cancer (THE ASCO POST) - "'Overall survival consistently favored nivolumab plus chemotherapy with longer follow-up across multiple prespecified subgroups in all randomized patients, and the benefit was enriched at higher PD-L1 cutoffs,' Dr. Janjigian said. She noted the benefit in the all-randomized population extended 'to patients whom we would think would do poorly, such as [those with] liver metastasis, and irrespective of tumor location.'"

Media quote

Expert Point of View: Laura Goff, MD, MSCI (THE ASCO POST) - "Invited discussant Laura Goff, MD, MSCI...said that with the results of NAPOLI-3, clinicians have a third effective first-line regimen for metastatic pancreatic cancer."

Media quote

ASCO GI 2023 NAPOLI-3 Randomized, Open-Label Phase 3 Study: Liposomal Irinotecan + 5-Fluorouracil/Leucovorin + Oxaliplatin (NALIRIFOX) vs. nab-Paclitaxel + Gemcitabine in Treatment-Naïve Patients With mPDAC (VuMedi) - https://www.vumedi.com/video/asco-gi-2023-napoli-3-randomized-open-label-phase-3-study-liposomal-irinotecan-5-fluorouracilleucovo/

Video

Metastatic Colorectal Cancer: Selecting Treatment for Brain Metastases (MedPageToday) - "Elaine is a 36-year-old woman with KRAS/BRAF wild-type HER2-positive de novo metastatic colorectal cancer (ECOG performance status 1; Stage IV). Her first-line treatment included induction with leucovorin, fluorouracil, oxaliplatin, and bevacizumab followed by a non-oxaliplatin-containing maintenance chemotherapy regimen."

Online posting

Shah Explores Treatment Options for Patients With Advanced HER2+ Gastric Cancer (Targeted Oncology) - "During a live event, Manish A. Shah, MD, discussed the case of a 65-year-old man presented with new onset fatigue, upper abdominal pain that worsened with eating, and unintentional weight loss."

Media quote

Merrimack Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (Businesswire) - P3 | N=770 | NAPOLI 3 (NCT04083235) | Sponsor: Ipsen | "Merrimack Pharmaceuticals...announced that Ipsen, SA ('Ipsen') issued a press release today reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a treatment of first line metastatic pancreatic ductal adenocarcinoma (mPDAC)....The Ipsen press release indicates that the trial “met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and key secondary efficacy outcome of progression-free survival (PFS) also showed significant improvement over the comparator arm."

P3 data • Gastrointestinal Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer

Expert Point of View: Katrina S. Pedersen, MD, MS (THE ASCO POST) - "Dr. Pedersen questioned, however, whether nab-paclitaxel/gemcitabine alternating with FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) would produce even more benefit than alternating with FOLFOX. As she pointed out, FOLFIRINOX would have been the standard of care for patients with a good performance status who were young enough for it. 'The key takeaway is this is a very interesting study, but phase III validation is needed,' Dr. Pedersen concluded."

Media quote